<DOC>
	<DOCNO>NCT02656810</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics ( blood level ) two teriparatide product , PF708 Forteo , healthy subject .</brief_summary>
	<brief_title>A Comparison Study PF708 Forteo Healthy Subjects</brief_title>
	<detailed_description>This double-masked , randomize , two-treatment cross-over study healthy adult subject . Half subject randomize receive PF708 first Forteo second ( Sequence A ) , half randomize receive drug reverse sequence ( Sequence B ) ,</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Teriparatide</mesh_term>
	<criteria>Male female age 1850 year time Informed Consent . Able understand sign write Informed Consent Form ( ICF ) . History positive test result human immunodeficiency virus ( HIV ) , hepatitis C virus [ test hepatitis C virus antibody ( HCV Ab ) ] hepatitis B virus [ test hepatitis B surface antigen ( HBsAg ) ] . Female subject pregnant positive pregnancy test result , currently breastfeed , plan become pregnant course study . Blood donation ( great equal 500 mL ) within 30 day prior screen . History Paget 's disease bone . History prior external beam implant radiation therapy involve skeleton . Active urolithiasis primary hyperparathyroidism . History alcohol substance abuse within 3 year prior screen . Previous treatment , include investigational purpose , product ( e.g. , Forteo , Natpara ) derive human parathyroid hormone ( PTH ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>